Document Detail

Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss.
MedLine Citation:
PMID:  10992173     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Our purpose was to study combinations of estradiol and gestodene for prevention of bone loss in early postmenopausal women. STUDY DESIGN: We randomly assigned 278 healthy, early postmenopausal women to receive either 2 mg 17beta-estradiol sequentially combined with 25 microg gestodene (group 2/25s), 2 mg estradiol sequentially combined with 50 microg gestodene (group 2/50s), 1 mg estradiol sequentially combined with 25 microg gestodene (group 1/25s), 1 mg estradiol continuously combined with 25 mg gestodene (group 1/25c), or placebo. RESULTS: After 3 years the changes in bone mineral density of the spine were as follows (mean +/- SEM): group 2/25s, 7. 41% +/- 0.72%; group 2/50s, 8.53% +/- 0.90%; group 1.25s, 6.67% +/- 0.88%; group 1/25c, 4.44% +/- 0.59%; and placebo group, -2.03% +/- 0. 64%. The changes in bone mineral density were mirrored in the biochemical bone markers. The average responses for the urinary C-terminal telopeptide fragments of type I collagen corrected for creatinine excretion were as follows (mean of baseline +/- SEM): group 2/25s, -68.8% +/- 0.03%; group 2/50s, -72.8% +/- 0.02%; group 1/25s, -60.7% +/- 0.03%; group 1/25c, -52.28% +/- 0.04%; and placebo group, 6.5% +/- 0.09%. Beneficial lipid effects were found in all active groups. The decreases in low-density lipoprotein were as follows (mean +/- SEM): group 2/25s, -13.7% +/- 3.0%; group 2/50s, -14.6% +/- 3.2%; group 1/25s, -9.28% +/- 2.2%; group 1/25c, -9.92% +/- 2.4%; and placebo group, 1.53% +/- 1.9%. CONCLUSION: These results demonstrate that estradiol therapy with 1 mg estradiol is fully protective against early postmenopausal bone loss.
N H Bjarnason; I Byrjalsen; C Hassager; J Haarbo; C Christiansen
Related Documents :
17683173 - Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in c...
9389803 - Avoidance of oocyte retrieval on the weekend through the use of scheduled ovarian hyper...
20502133 - Replacing a dopamine agonist by the comt-inhibitor tolcapone as an adjunct to l-dopa in...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  183     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2000-10-10     Completed Date:  2000-10-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  550-60     Citation Subset:  AIM; IM    
Center for Clinical and Basic Research, Ballerup, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density
Collagen / urine
Collagen Type I
Creatinine / urine
Estradiol / administration & dosage*,  blood,  therapeutic use
Estrone / blood
Follicle Stimulating Hormone / blood
Lipids / blood
Lipoproteins, LDL / blood
Middle Aged
Norpregnenes / administration & dosage*,  blood,  therapeutic use
Osteoporosis, Postmenopausal / prevention & control*
Peptides / urine
Progesterone Congeners / administration & dosage*,  blood,  therapeutic use
Reg. No./Substance:
0/Collagen Type I; 0/Lipids; 0/Lipoproteins, LDL; 0/Norpregnenes; 0/Peptides; 0/Placebos; 0/Progesterone Congeners; 0/collagen type I trimeric cross-linked peptide; 50-28-2/Estradiol; 53-16-7/Estrone; 60-27-5/Creatinine; 60282-87-3/Gestodene; 9002-68-0/Follicle Stimulating Hormone; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identification of at-risk women for osteoporosis screening.
Next Document:  A population-based five-year follow-up study of cervical human papillomavirus infection.